Browsing Tag
ALS
8 posts
Can Coya Therapeutics de-risk IL-2 manufacturing ahead of trial results? Inside the $11.1m raise
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy’s to scale COYA 302 IL-2 manufacturing. Find out what it means for investors.
BrainStorm Cell Therapeutics (OTCQB: BCLI) narrows Q3 2025 loss as ALS trial preps advance and cash runway tightens
BrainStorm Cell Therapeutics narrows Q3 loss and prepares for pivotal ALS trial. Find out why 2026 could be a make-or-break year for the biotech company.
Why investors are watching Neurizon Therapeutics (ASX: NUZ) ahead of FDA clearance for NUZ-001
Neurizon Therapeutics (ASX: NUZ) secures A$5m to fund ALS trial entry. Can NUZ-001 succeed in the HEALEY ALS Platform Trial and change the biotech landscape?
Can pridopidine finally change the trajectory of Huntington’s disease progression?
Can pridopidine change the course of Huntington’s disease? Explore key data from the Nature Medicine study and what’s next for Prilenia’s regulatory path.
Coya Therapeutics gets FDA green light for Phase 2 ALS trial with COYA 302
Coya Therapeutics receives FDA clearance to initiate a Phase 2 trial of COYA 302 for ALS. Find out what this means for investors and the ALS drug pipeline.
Why is the brain–computer interface market growing so fast—and what does it mean for healthcare?
Discover how brain–computer interfaces may reshape mental health, education, and neurodegenerative treatment – read the latest insights now!
Amylyx Pharmaceuticals resumes AMX0114 clinical trials for ALS after FDA clears path
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has announced that the U.S. Food and Drug Administration (FDA) has lifted the…
IM Cannabis and Kadimastem announce reverse merger deal
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), known for its significant strides in the medical cannabis sector, has…